CASP1 and Insulin resistance: To further determine whether insulin resistance observed in Kir6.1 KO mice was indeed caused by enhanced NLRP3 inflammasome activation, Kir6.1 KO mice were treated with the caspase-1-specific inhibitor AC-YVAD-CMK via intraperitoneal injection at a dose of 40 mg/kg for 7 days, and blood glucose and insulin levels were subsequently measured.